Novel glucose-lowering agents that benefit diabetic foot: icing on the cake

The prevalence of diabetes mellitus is increasing and is linked to several complications, including diabetic foot. Novel glucose-lowering agents are sought that also have beneficial effects in reducing diabetic complications. Among the novel glucose-lowering agents demonstrating clinical promise, th...

Full description

Saved in:
Bibliographic Details
Main Authors: Qin Li, Shiyan Yu, Shunli Rui, Xiaobu Lin, Yi Yuan, David G. Armstrong, Yi Xu, Wuquan Deng
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Endocrinology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fendo.2025.1581403/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849416869737398272
author Qin Li
Shiyan Yu
Shunli Rui
Xiaobu Lin
Yi Yuan
David G. Armstrong
Yi Xu
Yi Xu
Wuquan Deng
Wuquan Deng
author_facet Qin Li
Shiyan Yu
Shunli Rui
Xiaobu Lin
Yi Yuan
David G. Armstrong
Yi Xu
Yi Xu
Wuquan Deng
Wuquan Deng
author_sort Qin Li
collection DOAJ
description The prevalence of diabetes mellitus is increasing and is linked to several complications, including diabetic foot. Novel glucose-lowering agents are sought that also have beneficial effects in reducing diabetic complications. Among the novel glucose-lowering agents demonstrating clinical promise, three classes stand out: dipeptidyl peptidase-4 inhibitors (DPP-4is), glucagon-like peptide-1 receptor agonists (GLP-1RAs), and sodium-glucose cotransporter-2 inhibitors (SGLT2is). Some of these agents provide cardiovascular and kidney benefits, and there is evidence suggesting they also offer protective effects against diabetic foot complications. In this review, we summarize the preclinical and clinical evidence proof these three glucose-lowering agents for diabetic foot, highlighting their potential in enhancing diabetic wound healing and limb preservation. In conclusion, existing available trials have shown that certain DPP-4is and GLP-1RAs possess protective effects against diabetic foot conditions. However, SGLT2is have not demonstrated a significant protective effect. We encourage larger-scale studies on the protective effects of these three types of drugs for diabetic foot to guide physicians in providing personalized treatment strategies, achieving blood glucose targets, and promoting the healing of chronic wounds in patients.
format Article
id doaj-art-d6c63c36b55d48559c5a6ae6c261ea50
institution Kabale University
issn 1664-2392
language English
publishDate 2025-07-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Endocrinology
spelling doaj-art-d6c63c36b55d48559c5a6ae6c261ea502025-08-20T03:33:02ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922025-07-011610.3389/fendo.2025.15814031581403Novel glucose-lowering agents that benefit diabetic foot: icing on the cakeQin Li0Shiyan Yu1Shunli Rui2Xiaobu Lin3Yi Yuan4David G. Armstrong5Yi Xu6Yi Xu7Wuquan Deng8Wuquan Deng9Department of Endocrinology and Diabetic Foot Center, Chongqing University Central Hospital, Chongqing Emergency Medical Centre, School of Medicine, Chongqing University, Chongqing, ChinaDepartment of Endocrinology and Diabetic Foot Center, Chongqing University Central Hospital, Chongqing Emergency Medical Centre, School of Medicine, Chongqing University, Chongqing, ChinaDepartment of Endocrinology and Diabetic Foot Center, Chongqing University Central Hospital, Chongqing Emergency Medical Centre, School of Medicine, Chongqing University, Chongqing, ChinaDepartment of Endocrinology and Diabetic Foot Center, Chongqing University Central Hospital, Chongqing Emergency Medical Centre, School of Medicine, Chongqing University, Chongqing, ChinaDepartment of Endocrinology and Diabetic Foot Center, Chongqing University Central Hospital, Chongqing Emergency Medical Centre, School of Medicine, Chongqing University, Chongqing, ChinaDepartment of Surgery, Keck School of Medicine of University of Southern California, Los Angeles, CA, United StatesDepartment of Endocrinology and Diabetic Foot Center, Chongqing University Central Hospital, Chongqing Emergency Medical Centre, School of Medicine, Chongqing University, Chongqing, ChinaChongqing Liang Jiang New Area Traditional Chinese Medicine Hospital, Chongqing, ChinaDepartment of Endocrinology and Diabetic Foot Center, Chongqing University Central Hospital, Chongqing Emergency Medical Centre, School of Medicine, Chongqing University, Chongqing, ChinaDepartment of Population Health Sciences, King's College London, London, United KingdomThe prevalence of diabetes mellitus is increasing and is linked to several complications, including diabetic foot. Novel glucose-lowering agents are sought that also have beneficial effects in reducing diabetic complications. Among the novel glucose-lowering agents demonstrating clinical promise, three classes stand out: dipeptidyl peptidase-4 inhibitors (DPP-4is), glucagon-like peptide-1 receptor agonists (GLP-1RAs), and sodium-glucose cotransporter-2 inhibitors (SGLT2is). Some of these agents provide cardiovascular and kidney benefits, and there is evidence suggesting they also offer protective effects against diabetic foot complications. In this review, we summarize the preclinical and clinical evidence proof these three glucose-lowering agents for diabetic foot, highlighting their potential in enhancing diabetic wound healing and limb preservation. In conclusion, existing available trials have shown that certain DPP-4is and GLP-1RAs possess protective effects against diabetic foot conditions. However, SGLT2is have not demonstrated a significant protective effect. We encourage larger-scale studies on the protective effects of these three types of drugs for diabetic foot to guide physicians in providing personalized treatment strategies, achieving blood glucose targets, and promoting the healing of chronic wounds in patients.https://www.frontiersin.org/articles/10.3389/fendo.2025.1581403/fulldiabetic footnovel glucose-lowering agentsdipeptidyl peptidase-4 inhibitorsglucagon-like peptide-1 receptor agonistssodium-glucose cotransporter-2 inhibitors
spellingShingle Qin Li
Shiyan Yu
Shunli Rui
Xiaobu Lin
Yi Yuan
David G. Armstrong
Yi Xu
Yi Xu
Wuquan Deng
Wuquan Deng
Novel glucose-lowering agents that benefit diabetic foot: icing on the cake
Frontiers in Endocrinology
diabetic foot
novel glucose-lowering agents
dipeptidyl peptidase-4 inhibitors
glucagon-like peptide-1 receptor agonists
sodium-glucose cotransporter-2 inhibitors
title Novel glucose-lowering agents that benefit diabetic foot: icing on the cake
title_full Novel glucose-lowering agents that benefit diabetic foot: icing on the cake
title_fullStr Novel glucose-lowering agents that benefit diabetic foot: icing on the cake
title_full_unstemmed Novel glucose-lowering agents that benefit diabetic foot: icing on the cake
title_short Novel glucose-lowering agents that benefit diabetic foot: icing on the cake
title_sort novel glucose lowering agents that benefit diabetic foot icing on the cake
topic diabetic foot
novel glucose-lowering agents
dipeptidyl peptidase-4 inhibitors
glucagon-like peptide-1 receptor agonists
sodium-glucose cotransporter-2 inhibitors
url https://www.frontiersin.org/articles/10.3389/fendo.2025.1581403/full
work_keys_str_mv AT qinli novelglucoseloweringagentsthatbenefitdiabeticfooticingonthecake
AT shiyanyu novelglucoseloweringagentsthatbenefitdiabeticfooticingonthecake
AT shunlirui novelglucoseloweringagentsthatbenefitdiabeticfooticingonthecake
AT xiaobulin novelglucoseloweringagentsthatbenefitdiabeticfooticingonthecake
AT yiyuan novelglucoseloweringagentsthatbenefitdiabeticfooticingonthecake
AT davidgarmstrong novelglucoseloweringagentsthatbenefitdiabeticfooticingonthecake
AT yixu novelglucoseloweringagentsthatbenefitdiabeticfooticingonthecake
AT yixu novelglucoseloweringagentsthatbenefitdiabeticfooticingonthecake
AT wuquandeng novelglucoseloweringagentsthatbenefitdiabeticfooticingonthecake
AT wuquandeng novelglucoseloweringagentsthatbenefitdiabeticfooticingonthecake